Tags

Type your tag names separated by a space and hit enter

Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial.
J Am Acad Dermatol. 2006 Mar; 54(3 Suppl 2):S112-9.JA

Abstract

BACKGROUND

Etanercept provides rapid, significant improvement in psoriatic symptoms and disease.

OBJECTIVE

The effectiveness of continued etanercept treatment beyond 24 weeks in patients who initially did not achieve at least a 50% improvement from baseline in the Psoriasis Area and Severity Index (PASI 50) was assessed.

METHODS

Patients with moderate to severe plaque psoriasis received 50 mg open-label, subcutaneous etanercept per week after completing blinded therapy with placebo or 1 of 3 doses of etanercept. The PASI was measured.

RESULTS

Irrespective of prior dosing regimens, 43% of 157 patients who did not attain PASI 50 responses at week 24 achieved PASI 50 responses at week 36; 55% achieved PASI 50 responses at week 60. Etanercept was safe and well tolerated.

LIMITATIONS

Interpretation of these results is limited by the open-label design of the analysis.

CONCLUSION

More than half of patients who initially had an inadequate response to treatment achieved satisfactory responses with continued etanercept therapy. The safety profile of etanercept in these patients and in patients who had more immediate responses was similar.

Authors+Show Affiliations

Krueger GG
University of Utah Health Sciences Center, Salt Lake City, Utah 84132-0001, USA. krueger@derm.med.utah.edu
Elewski B
No affiliation info available
Papp K
No affiliation info available
Wang A
No affiliation info available
Zitnik R
No affiliation info available
Jahreis A
No affiliation info available

MeSH

AdultDrug Administration ScheduleEtanerceptFemaleHumansImmunoglobulin GImmunosuppressive AgentsMaleMiddle AgedPsoriasisRandomized Controlled Trials as TopicReceptors, Tumor Necrosis FactorTreatment Outcome

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16488321

Citation

Krueger, Gerald G., et al. "Patients With Psoriasis Respond to Continuous Open-label Etanercept Treatment After Initial Incomplete Response in a Randomized, Placebo-controlled Trial." Journal of the American Academy of Dermatology, vol. 54, no. 3 Suppl 2, 2006, pp. S112-9.
Krueger GG, Elewski B, Papp K, et al. Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial. J Am Acad Dermatol. 2006;54(3 Suppl 2):S112-9.
Krueger, G. G., Elewski, B., Papp, K., Wang, A., Zitnik, R., & Jahreis, A. (2006). Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial. Journal of the American Academy of Dermatology, 54(3 Suppl 2), S112-9.
Krueger GG, et al. Patients With Psoriasis Respond to Continuous Open-label Etanercept Treatment After Initial Incomplete Response in a Randomized, Placebo-controlled Trial. J Am Acad Dermatol. 2006;54(3 Suppl 2):S112-9. PubMed PMID: 16488321.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial. AU - Krueger,Gerald G, AU - Elewski,Boni, AU - Papp,Kim, AU - Wang,Andrea, AU - Zitnik,Ralph, AU - Jahreis,Angelika, PY - 2005/06/01/received PY - 2005/09/29/revised PY - 2005/10/11/accepted PY - 2006/2/21/pubmed PY - 2006/3/8/medline PY - 2006/2/21/entrez SP - S112 EP - 9 JF - Journal of the American Academy of Dermatology JO - J Am Acad Dermatol VL - 54 IS - 3 Suppl 2 N2 - BACKGROUND: Etanercept provides rapid, significant improvement in psoriatic symptoms and disease. OBJECTIVE: The effectiveness of continued etanercept treatment beyond 24 weeks in patients who initially did not achieve at least a 50% improvement from baseline in the Psoriasis Area and Severity Index (PASI 50) was assessed. METHODS: Patients with moderate to severe plaque psoriasis received 50 mg open-label, subcutaneous etanercept per week after completing blinded therapy with placebo or 1 of 3 doses of etanercept. The PASI was measured. RESULTS: Irrespective of prior dosing regimens, 43% of 157 patients who did not attain PASI 50 responses at week 24 achieved PASI 50 responses at week 36; 55% achieved PASI 50 responses at week 60. Etanercept was safe and well tolerated. LIMITATIONS: Interpretation of these results is limited by the open-label design of the analysis. CONCLUSION: More than half of patients who initially had an inadequate response to treatment achieved satisfactory responses with continued etanercept therapy. The safety profile of etanercept in these patients and in patients who had more immediate responses was similar. SN - 1097-6787 UR - https://www.unboundmedicine.com/medline/citation/16488321/Patients_with_psoriasis_respond_to_continuous_open_label_etanercept_treatment_after_initial_incomplete_response_in_a_randomized_placebo_controlled_trial_ DB - PRIME DP - Unbound Medicine ER -